Shots:

• The US FDA has granted FTD to selinexor (NOX inhibitor) for the treatment of PBC. Additionally- the therapy has previously received ODD for PBC in the US & EU
• The P-II clinical trial of the therapy demonstrated anti-fibrotic activity as measured by Fibroscan and showed favorable tolerability profile along with the impact on fatigue
• The company plans to start P-II/III study for PBC in H2’21 based on results from the P-I study which evaluated higher doses of setanaxib in healthy volunteers

| Ref: Calliditas | Image: Calliditas